VITA 34 AG (V3V) - Total Liabilities
Based on the latest financial reports, VITA 34 AG (V3V) has total liabilities worth €162.84 Million EUR (≈ $190.38 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore V3V long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
VITA 34 AG - Total Liabilities Trend (2006–2025)
This chart illustrates how VITA 34 AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of VITA 34 AG.
VITA 34 AG Competitors by Total Liabilities
The table below lists competitors of VITA 34 AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Abra Information Technologies Ltd
TA:BBYL
|
Israel | ILA23.47 Million |
|
Arthavest Tbk
JK:ARTA
|
Indonesia | Rp22.61 Billion |
|
Bigbloc Construction Limited
NSE:BIGBLOC
|
India | Rs2.36 Billion |
|
Ikena Oncology Inc
NASDAQ:IKNA
|
USA | $10.26 Million |
|
Citizens Holding Company
NASDAQ:CIZN
|
USA | $1.49 Billion |
|
TEAM INC. DL-30
F:T9CA
|
Germany | €509.93 Million |
|
Introl S.A.
WAR:INL
|
Poland | zł281.16 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down VITA 34 AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VITA 34 AG (V3V) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 22.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VITA 34 AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VITA 34 AG (2006–2025)
The table below shows the annual total liabilities of VITA 34 AG from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €162.84 Million ≈ $190.38 Million |
+16.46% |
| 2024-12-31 | €139.83 Million ≈ $163.48 Million |
+3.13% |
| 2023-12-31 | €135.58 Million ≈ $158.51 Million |
-0.06% |
| 2022-12-31 | €135.66 Million ≈ $158.60 Million |
-0.26% |
| 2021-12-31 | €136.00 Million ≈ $159.00 Million |
+370.13% |
| 2020-12-31 | €28.93 Million ≈ $33.82 Million |
-6.17% |
| 2019-12-31 | €30.83 Million ≈ $36.04 Million |
+3.56% |
| 2018-12-31 | €29.77 Million ≈ $34.80 Million |
-7.88% |
| 2017-12-31 | €32.32 Million ≈ $37.78 Million |
+63.45% |
| 2016-12-31 | €19.77 Million ≈ $23.12 Million |
-1.26% |
| 2015-12-31 | €20.03 Million ≈ $23.41 Million |
+34.44% |
| 2014-12-31 | €14.90 Million ≈ $17.41 Million |
+3.91% |
| 2013-12-31 | €14.34 Million ≈ $16.76 Million |
-11.14% |
| 2012-12-31 | €16.13 Million ≈ $18.86 Million |
+9.52% |
| 2011-12-31 | €14.73 Million ≈ $17.22 Million |
-17.56% |
| 2010-12-31 | €17.87 Million ≈ $20.89 Million |
+45.56% |
| 2009-12-31 | €12.28 Million ≈ $14.35 Million |
+0.61% |
| 2008-12-31 | €12.20 Million ≈ $14.27 Million |
-2.61% |
| 2007-12-31 | €12.53 Million ≈ $14.65 Million |
-2.68% |
| 2006-12-31 | €12.88 Million ≈ $15.05 Million |
-- |
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more